Patents Assigned to Trillium Therapeutics Inc.
-
Patent number: 8729247Abstract: A soluble multimeric protein or polypeptide is disclosed that is able to inhibit interaction of leukocyte Fc? receptors (Fc?R) and immunoglobulin G (IgG). The protein or polypeptide comprises two or more linked Fc binding regions, at least one of which is derived from an Fc?R type receptor and, particularly, Fc?RIIa. Also described are polynucleotide molecules encoding the protein or polypeptide and the use thereof in methods of treating a subject for an immune-complex (IC)-mediated inflammatory disease.Type: GrantFiled: December 6, 2012Date of Patent: May 20, 2014Assignee: Trillium Therapeutics, Inc.Inventors: Phillip Mark Hogarth, Bruce David Wines
-
Publication number: 20130102532Abstract: HB-EGF is exploited to treat conditions associated with enhanced urothelium permeability, including interstitial cystitis.Type: ApplicationFiled: April 12, 2011Publication date: April 25, 2013Applicant: TRILLIUM THERAPEUTICS INC.Inventors: Robert Uger, Penka Petrova
-
Publication number: 20120264145Abstract: The disclosure relates to methods for identifying a subject having elevated CD200 levels and/or comprising cells overexpressing CD200, the method comprising the step of assaying a biological fluid from the subject to determine a level of soluble CD200, wherein a level above control indicates the subject has elevated CD200 levels. Diagnostic methods, methods of monitoring prognosis and methods of medical treatment relating to CD200 associated medical conditions are also provided. The disclosure also provides assays and kits useful in the diagnosis of a medical condition associated with elevated CD200 and/or comprising cells overexpressing CD200.Type: ApplicationFiled: May 18, 2012Publication date: October 18, 2012Applicant: TRILLIUM THERAPEUTICS INC.Inventors: Reginald M. Gorczynski, Karrie Ka Wai Wong
-
Patent number: 8206897Abstract: The disclosure relates to methods for identifying a subject having elevated CD200 levels and/or comprising cells overexpressing CD200, the method comprising the step of assaying a biological fluid from the subject to determine a level of soluble CD200, wherein a level above control indicates the subject has elevated CD200 levels. Diagnostic methods, methods of monitoring prognosis and methods of medical treatment relating to CD200 associated medical conditions are also provided. The disclosure also provides assays and kits useful in the diagnosis of a medical condition associated with elevated CD200 and/or comprising cells overexpressing CD200.Type: GrantFiled: July 29, 2008Date of Patent: June 26, 2012Assignee: Trillium Therapeutics Inc.Inventors: Reginald M. Gorczynski, Karrie Ka Wai Wong
-
Patent number: 8187598Abstract: Methods and compositions for regulating immunity are disclosed. For enhancing an immune response, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For suppressing an immune response, an OX-2 protein or a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in preventing graft rejection, fetal loss, autoimmune disease, allergies and in inducing tumor cell growth.Type: GrantFiled: February 11, 2011Date of Patent: May 29, 2012Assignee: Trillium Therapeutics Inc.Inventors: Reginald M. Gorczynski, David A. Clark
-
Publication number: 20110206668Abstract: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of an agent that inhibits CD200. Such methods are useful in treating cancer.Type: ApplicationFiled: February 3, 2011Publication date: August 25, 2011Applicant: TRILLIUM THERAPEUTICS INC.Inventors: REGINALD M. GORCZYNSKI, DAVID A. CLARK
-
Publication number: 20110129466Abstract: Methods and compositions for regulating immunity are disclosed. For enhancing an immune response, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For suppressing an immune response, an OX-2 protein or a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in preventing graft rejection, fetal loss, autoimmune disease, allergies and in inducing tumor cell growth.Type: ApplicationFiled: February 11, 2011Publication date: June 2, 2011Applicant: TRILLIUM THERAPEUTICS INC.Inventors: REGINALD M. GORCZYNSKI, DAVID A. CLARK
-
Patent number: 7910770Abstract: The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl ring substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc receptor activity using such compounds. A method for obtaining a compound which modulates Fc receptor activity is also provided, the method comprising: (a) providing or designing compounds having structural characteristics to fit in the groove of the Fc?RIIa structure; and (b) screening the compounds for modulating activity on the Fc receptor.Type: GrantFiled: February 1, 2008Date of Patent: March 22, 2011Assignee: Trillium Therapeutics Inc.Inventors: Mark Phillip Hogarth, Geoffrey Allan Pietersz, Gerard Peter Moloney
-
Patent number: 7902151Abstract: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of an agent that inhibits CD200. Such methods are useful in treating cancer.Type: GrantFiled: May 22, 2009Date of Patent: March 8, 2011Assignee: Trillium Therapeutics Inc.Inventors: Reginald M. Gorczynski, David A. Clark
-
Patent number: 7887798Abstract: Methods and compositions for regulating immunity are disclosed. For enhancing an immune response, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For suppressing an immune response, an OX-2 protein or a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in preventing graft rejection, fetal loss, autoimmune disease, allergies and in inducing tumor cell growth.Type: GrantFiled: October 7, 2008Date of Patent: February 15, 2011Assignee: Trillium Therapeutics Inc.Inventors: Reginald M. Gorczynski, David A. Clark
-
Publication number: 20090232825Abstract: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of an agent that inhibits CD200. Such methods are useful in treating cancer.Type: ApplicationFiled: May 22, 2009Publication date: September 17, 2009Applicant: TRILLIUM THERAPEUTICS INC.Inventors: REGINALD M. GORCZYNSKI, DAVID A. CLARK
-
Patent number: 7553811Abstract: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of an agent that inhibits CD200. Such methods are useful in treating cancer.Type: GrantFiled: April 18, 2007Date of Patent: June 30, 2009Assignee: Trillium Therapeutics Inc.Inventors: Reginald M. Gorczynski, David A. Clark
-
Publication number: 20090053222Abstract: Methods and compositions for regulating immunity are disclosed. For enhancing an immune response, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For suppressing an immune response, an OX-2 protein or a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in preventing graft rejection, fetal loss, autoimmune disease, allergies and in inducing tumor cell growth.Type: ApplicationFiled: October 7, 2008Publication date: February 26, 2009Applicant: TRILLIUM THERAPEUTICS INC.Inventors: REGINALD M. GORCZYNSKI, DAVID A. CLARK
-
Patent number: 7452536Abstract: Methods and compositions for regulating immunity are disclosed. For enhancing an immune response, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For suppressing an immune response, an OX-2 protein or a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in preventing graft rejection, fetal loss, autoimmune disease, allergies and in inducing tumor cell growth.Type: GrantFiled: May 25, 2007Date of Patent: November 18, 2008Assignee: Trillium Therapeutics Inc.Inventors: Reginald M. Gorczynski, David A. Clark
-
Publication number: 20080146632Abstract: The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl zing substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc receptor activity using such compounds. A method for obtaining a compound which modulates Fc receptor activity is also provided, the method comprising: (a) providing or designing compounds having structural characteristics to fit in the groove of the Fc?RIIa structure; and (b) screening the compounds for modulating activity on the Fc receptor.Type: ApplicationFiled: February 1, 2008Publication date: June 19, 2008Applicant: TRILLIUM THERAPEUTICS, INC.Inventors: Mark Phillip Hogarth, Geoffrey Allan Pietersz, Gerard Peter Moloney
-
Patent number: 7368535Abstract: The present invention relates to CD200 receptor isoforms and modulators thereof and their use in methods of immune modulation and pharmaceutical compositions.Type: GrantFiled: May 24, 2002Date of Patent: May 6, 2008Assignee: Trillium Therapeutics Inc.Inventors: Reginald M. Gorczynski, Philip Marsden
-
Patent number: 7351875Abstract: The present invention provides a Fc?RIIa transgenic non-human animal model for autoimmune disease, particularly arthritis. This invention also provides a method of using this model to screen compounds that can reduce aberrant immune activity including aberrant immune complex formation aberrant immune complex clearance and immune complex induced inflammation. This invention also provides means of using this model to treat or prevent autoimmune disease.Type: GrantFiled: June 6, 2003Date of Patent: April 1, 2008Assignee: Trillium Therapeutics, Inc.Inventors: Phillip Mark Hogarth, Patricia Lesley Mottram, Caroline Tan Sardjono
-
Patent number: 7332631Abstract: The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl ring substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc receptor activity using such compounds. A method for obtaining a compound which modulates Fc receptor activity is also provided, the method comprising: (a) providing or designing compounds having structural characteristics to fit in the groove of the Fc?RIIa structure; and (b) screening the compounds for modulating activity on the Fc receptor.Type: GrantFiled: December 24, 2003Date of Patent: February 19, 2008Assignee: Trillium Therapeutics Inc.Inventors: Mark Phillip Hogarth, Geoffrey Allan Pietersz, Gerard Peter Moloney
-
Publication number: 20080008700Abstract: A soluble multimeric protein or polypeptide is disclosed that is able to inhibit interaction of leukocyte Fc? receptors (Fc?R) and immunoglobulin G (IgG). The protein or polypeptide comprises two or more linked Fc binding regions, at least one of which is derived from an Fc?R type receptor and, particularly, Fc?RIIa. Also described are polynucleotide molecules encoding the protein or polypeptide and the use thereof in methods of treating a subject for an immune-complex (IC)-mediated inflammatory disease.Type: ApplicationFiled: June 13, 2007Publication date: January 10, 2008Applicant: TRILLIUM THERAPEUTICS, INC.Inventors: Phillip Hogarth, Bruce Wines
-
Patent number: 7291330Abstract: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of an agent that inhibits MD-1 with or without an OX-2 protein or a nucleic acid encoding an OX-2 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of MD-1 or an agent that activates or stimulates MD-1.Type: GrantFiled: March 16, 2001Date of Patent: November 6, 2007Assignee: Trillium Therapeutics Inc.Inventors: Reginald M. Gorczynski, David A. Clark